Nifty
Sensex
:
:
10763.40
35774.88
81.20 (0.76%)
317.72 (0.90%)

Pharmaceuticals & Drugs

Rating :
75/99

BSE: 524816 | NSE: NATCOPHARM

744.40
10.90 (1.49%)
19-Nov-2018 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  740.00
  •  749.00
  •  738.15
  •  733.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  110344
  •  821.40
  •  1050.00
  •  636.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 13,580.94
  • 15.41
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 13,570.44
  • 1.12%
  • 3.97

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.34%
  • 0.00%
  • 17.19%
  • FII
  • DII
  • Others
  • 0.72%
  • 5.38%
  • 28.37%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.29
  • 24.21
  • 24.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 27.64
  • 38.94
  • 27.77

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 31.81
  • 46.62
  • 64.26

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.97
  • 38.87
  • 36.85

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.01
  • 6.65
  • 7.12

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.69
  • 25.48
  • 26.19

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
543.50
426.70
27.37%
538.60
445.30
20.95%
767.80
577.80
32.88%
562.20
679.00
-17.20%
Expenses
323.00
304.80
5.97%
321.00
308.60
4.02%
384.50
336.70
14.20%
275.70
418.80
-34.17%
EBITDA
220.50
121.90
80.89%
217.60
136.70
59.18%
383.30
241.10
58.98%
286.50
260.20
10.11%
EBIDTM
40.57%
28.57%
40.40%
30.70%
49.92%
41.73%
50.96%
38.32%
Other Income
40.00
5.50
627.27%
35.90
3.40
955.88%
20.10
-0.60
-
11.40
6.10
86.89%
Interest
5.00
4.20
19.05%
2.80
3.90
-28.21%
3.00
6.40
-53.12%
4.30
4.60
-6.52%
Depreciation
20.20
16.00
26.25%
18.40
15.00
22.67%
18.00
13.50
33.33%
17.20
13.70
25.55%
PBT
235.30
107.20
119.50%
232.30
121.20
91.67%
382.40
220.60
73.35%
276.40
248.00
11.45%
Tax
53.70
22.80
135.53%
51.20
27.50
86.18%
82.70
44.20
87.10%
59.00
53.10
11.11%
PAT
181.60
84.40
115.17%
181.10
93.70
93.28%
299.70
176.40
69.90%
217.40
194.90
11.54%
PATM
33.41%
19.78%
33.62%
21.04%
39.03%
30.53%
38.67%
28.70%
EPS
9.89
4.86
103.50%
9.84
5.39
82.56%
16.25
10.13
60.41%
11.79
11.18
5.46%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
2,412.10
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
459.68
456.70
443.57
Net Sales Growth
13.31%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
13.93%
0.65%
2.96%
 
Cost Of Goods Sold
371.00
411.10
599.10
341.10
242.37
233.23
242.80
203.08
186.08
210.06
219.60
Gross Profit
2,041.10
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
273.60
246.64
223.96
GP Margin
84.62%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
59.52%
54.00%
50.49%
Total Expenditure
1,304.20
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
369.11
365.29
362.70
Power & Fuel Cost
-
56.20
50.50
43.70
43.24
44.77
38.75
26.88
21.41
15.13
15.84
% Of Sales
-
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
4.66%
3.31%
3.57%
Employee Cost
-
325.60
243.20
189.60
136.92
112.77
102.29
80.05
66.39
57.25
53.93
% Of Sales
-
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
14.44%
12.54%
12.16%
Manufacturing Exp.
-
160.40
141.20
105.20
73.04
76.57
65.10
43.32
40.18
38.80
34.84
% Of Sales
-
7.34%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
8.74%
8.50%
7.85%
General & Admin Exp.
-
105.50
88.10
73.40
63.66
56.21
39.49
32.37
27.32
19.61
19.85
% Of Sales
-
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
5.94%
4.29%
4.48%
Selling & Distn. Exp.
-
136.90
143.20
91.60
37.36
26.16
14.82
19.02
13.24
12.56
10.90
% Of Sales
-
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
2.88%
2.75%
2.46%
Miscellaneous Exp.
-
60.70
71.50
24.10
15.31
9.85
7.36
9.66
14.50
11.88
10.90
% Of Sales
-
2.78%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
3.15%
2.60%
1.74%
EBITDA
1,107.90
928.40
683.40
272.60
213.38
179.33
149.93
109.34
90.57
91.41
80.87
EBITDA Margin
45.93%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
19.70%
20.02%
18.23%
Other Income
107.40
40.40
13.90
9.90
14.91
16.71
12.41
9.14
4.64
4.62
4.94
Interest
15.10
15.40
18.50
22.90
31.68
36.62
26.31
23.04
14.20
14.69
15.11
Depreciation
73.80
66.20
54.40
51.00
47.27
30.44
22.12
15.91
15.88
19.73
14.06
PBT
1,126.40
887.20
624.40
208.60
149.34
128.98
113.90
79.54
65.12
61.61
56.64
Tax
246.60
192.00
139.50
52.80
3.95
30.87
36.44
21.07
13.21
13.66
11.29
Tax Rate
21.89%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
20.29%
22.17%
19.93%
PAT
879.80
696.20
486.00
157.10
134.62
102.74
71.87
59.61
53.51
48.72
43.97
PAT before Minority Interest
881.50
695.20
484.90
155.80
130.27
98.11
65.88
58.47
51.91
47.95
45.35
Minority Interest
1.70
1.00
1.10
1.30
4.35
4.63
5.99
1.14
1.60
0.77
-1.38
PAT Margin
36.47%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
11.64%
10.67%
9.91%
PAT Growth
60.14%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
11.40%
9.83%
10.80%
 
Unadjusted EPS
47.77
39.26
27.89
9.14
8.13
32.16
23.01
20.53
19.01
17.32
15.68

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
352.43
305.74
259.12
Share Capital
36.90
34.90
34.80
33.23
33.07
31.37
31.15
28.15
28.15
28.04
Total Reserves
3,011.10
1,599.00
1,251.20
812.82
692.80
502.17
442.49
324.29
277.59
229.58
Non-Current Liabilities
47.10
37.70
28.00
119.23
150.67
191.46
171.34
160.44
146.34
150.28
Secured Loans
0.00
0.00
0.00
94.03
92.20
135.62
133.88
125.21
114.02
120.67
Unsecured Loans
0.00
0.00
0.00
2.99
3.28
2.21
0.22
0.22
5.49
5.53
Long Term Provisions
32.40
21.90
12.50
9.50
11.09
8.62
6.59
8.67
0.00
0.00
Current Liabilities
592.00
626.50
493.10
413.74
312.28
344.87
259.35
193.38
97.29
109.67
Trade Payables
269.10
262.70
275.60
125.30
109.79
105.85
92.36
76.60
82.72
86.65
Other Current Liabilities
133.40
127.10
114.20
118.56
102.18
90.21
81.91
43.86
8.79
11.95
Short Term Borrowings
173.20
221.60
98.40
168.54
98.63
147.74
81.64
72.02
0.00
0.00
Short Term Provisions
16.30
15.10
4.90
1.33
1.69
1.07
3.44
0.91
5.78
11.06
Total Liabilities
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
707.31
554.31
526.02
Net Block
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
270.16
261.80
234.32
Gross Block
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
374.37
356.86
310.57
Accumulated Depreciation
389.00
325.70
273.20
225.82
171.11
140.57
117.34
104.21
95.06
76.25
Non Current Assets
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
460.37
361.69
315.52
Capital Work in Progress
480.00
336.30
211.80
128.96
123.78
105.84
164.43
75.98
39.60
46.96
Non Current Investment
8.10
0.10
0.10
1.57
1.57
1.54
61.79
61.79
60.29
34.24
Long Term Loans & Adv.
75.40
60.40
62.10
57.03
54.25
57.20
66.22
51.49
0.00
0.00
Other Non Current Assets
2.30
0.50
0.60
3.54
3.24
2.61
0.42
0.96
0.00
0.00
Current Assets
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
246.95
192.62
210.50
Current Investments
68.40
32.10
22.10
0.12
0.32
0.81
0.74
0.82
0.31
0.00
Inventories
438.40
348.90
357.30
220.00
181.12
146.02
110.39
102.23
77.44
80.29
Sundry Debtors
637.50
475.20
261.60
192.43
118.80
129.71
94.69
70.98
57.24
61.78
Cash & Bank
183.70
35.80
45.20
13.36
11.05
10.78
36.63
32.37
8.12
29.09
Other Current Assets
802.70
25.80
25.40
16.09
56.85
43.14
50.34
40.55
49.52
39.34
Short Term Loans & Adv.
749.50
169.50
125.40
40.97
52.46
38.85
41.84
36.73
49.05
38.57
Net Current Assets
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
53.56
95.32
100.83
Total Assets
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21
707.32
554.31
526.02

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
463.60
345.80
112.20
92.67
144.03
61.19
64.94
36.99
77.37
60.58
PBT
887.20
624.40
208.60
134.22
128.98
102.32
79.54
65.12
61.61
56.64
Adjustment
75.60
100.20
90.50
68.14
65.72
48.87
36.97
38.87
44.21
30.19
Changes in Working Capital
-294.70
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
-48.50
-11.24
-16.23
Cash after chg. in Working capital
668.10
471.60
158.40
116.41
178.58
83.80
88.54
55.49
94.58
70.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-204.50
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
-18.50
-17.21
-10.02
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
-88.78
-60.85
-73.87
Net Fixed Assets
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
-71.49
-38.56
-66.61
Net Investments
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
8.04
-20.13
-38.30
Others
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
-25.33
-2.16
31.04
Cash from Financing Activity
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
77.10
-34.14
15.86
Net Cash Inflow / Outflow
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
25.31
-17.63
2.57
Opening Cash & Equivalents
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
6.53
27.39
24.08
Closing Cash & Equivalent
21.70
23.50
-74.20
12.44
10.22
9.95
34.64
31.70
6.95
27.39

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
165.20
93.63
73.91
50.91
219.48
170.06
152.06
125.21
108.62
91.87
ROA
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
8.23%
8.88%
9.59%
ROE
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
15.77%
17.02%
19.36%
ROCE
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
15.90%
18.83%
20.58%
Fixed Asset Turnover
1.72
1.93
1.23
0.95
0.96
1.14
1.30
1.27
1.38
1.54
Receivable days
92.22
65.12
70.27
67.76
60.90
61.30
56.98
50.31
47.13
40.67
Inventory Days
65.25
62.41
89.35
87.33
80.17
70.04
73.13
70.50
62.46
60.60
Payable days
82.97
78.30
85.42
73.36
74.09
73.36
79.03
83.93
87.92
80.98
Cash Conversion Cycle
74.50
49.23
74.21
81.73
66.99
57.98
51.07
36.89
21.67
20.28
Total Debt/Equity
0.06
0.14
0.09
0.37
0.33
0.63
0.55
0.62
0.39
0.49
Interest Cover
58.61
34.75
10.11
5.24
4.52
4.89
4.45
5.59
5.19
4.75

Annual Reports:

News Update:


  • Natco Pharma - Quarterly Results
    5th Nov 2018, 14:49 PM

    Read More
  • Natco Pharma, Dr. Reddy’s file Doxorubicin Hydrochloride Liposome Injection in Europe
    13th Aug 2018, 14:29 PM

    Janssen’s brand Doxil is predominantly used for the treatment of metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.